Tag: Obstructive

Posted on

Obstructive sleep apnea risk increases with asthma: Study – Bel Marra Health


Bel Marra Health

Obstructive sleep apnea risk increases with asthma: Study
Bel Marra Health
Obstructive sleep apnea risk increases with asthma: Study Obstructive sleep apnea (OSA) risk increases with asthma, according to research. Extensive research confirmed the link between asthma and obstructive sleep apnea, but it was long unclear whether …

and more »

View full post on asthma – Google News

Posted on

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inahler;   Drug: Albuterol/Salbutamol
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified April 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Loop gain in severely obese women with obstructive sleep apnoea.

Loop gain in severely obese women with obstructive sleep apnoea.

Respir Physiol Neurobiol. 2015 Nov 15;

Authors: Bokov P, Essalhi M, Delclaux C

Abstract
Our objective was to assess whether obstructive sleep apnoea (OSA) patients were characterised by a reduced central CO2 controller gain (CG) and an enhanced plant gain (PG). We matched three groups of women (n=10 per group) enrolled in a previous study (Essalhi et al., J. Asthma. 50: 565-572, 2013): obese women with a respiratory disturbance index (RDI)?15/hour and with a RDI<15, and lean women without OSA (RDI<5). Tidal ventilation recordings during wakefulness with end-tidal PCO2 monitoring allowed the assessment of loop gain (LG) and its components (PG and CG). LG were similar for the three groups (p=0.844) while both PG and CG depicted significant differences (p=0.046 and p=0.011, respectively). Obese women with OSA were characterised by an increased PG and a reduced CG as compared to obese women without OSA. A negative relationship between CG and RDI (rho=-0.46, p=0.008) was evidenced. In conclusion, OSA in women is associated with a reduced central CO2 controller gain and an enhanced plant gain.

PMID: 26590323 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.

Eur J Intern Med. 2015 Jun 3;

Authors: Santus P, Radovanovic D, Paggiaro P, Papi A, Sanduzzi A, Scichilone N, Braido F

Abstract
Long-acting ?2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low ?2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an “as needed” treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.

PMID: 26049917 [PubMed – as supplied by publisher]

View full post on pubmed: asthma